Shiqiao Ye

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7913313/publications.pdf

Version: 2024-02-01

623734 752698 22 691 14 20 h-index citations g-index papers 22 22 22 1434 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Suppression of Autophagy in Osteocytes Mimics Skeletal Aging. Journal of Biological Chemistry, 2013, 288, 17432-17440.	3.4	165
2	Steap4 Plays a Critical Role in Osteoclastogenesis in Vitro by Regulating Cellular Iron/Reactive Oxygen Species (ROS) Levels and cAMP Response Element-binding Protein (CREB) Activation. Journal of Biological Chemistry, 2013, 288, 30064-30074.	3.4	71
3	MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood, 2016, 128, 2919-2930.	1.4	57
4	PLEKHM1/DEF8/RAB7 complex regulates lysosome positioning and bone homeostasis. JCI Insight, 2016, 1, e86330.	5.0	57
5	Downregulation of Notch Modulators, Tetraspanin 5 and 10, Inhibits Osteoclastogenesis in Vitro. Calcified Tissue International, 2014, 95, 209-217.	3.1	50
6	LIS1 Regulates Osteoclast Formation and Function through Its Interactions with Dynein/Dynactin and Plekhm1. PLoS ONE, 2011, 6, e27285.	2.5	42
7	Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma. PLoS ONE, 2013, 8, e74191.	2.5	39
8	Silencing neuroglobin enhances neuronal vulnerability to oxidative injury by down-regulating 14-3-3 \hat{I}^3 . Acta Pharmacologica Sinica, 2009, 30, 913-918.	6.1	38
9	Ubiquitin E3 Ligase LNX2 is Critical for Osteoclastogenesis In Vitro by Regulating M-CSF/RANKL Signaling and Notch2. Calcified Tissue International, 2015, 96, 465-475.	3.1	30
10	A simplified probe preparation for ELISA-based NF-lºB activity assay. Journal of Proteomics, 2005, 65, 20-29.	2.4	29
11	Disruption of the dynein-dynactin complex unveils motor-specific functions in osteoclast formation and bone resorption. Journal of Bone and Mineral Research, 2013, 28, 119-134.	2.8	29
12	MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. BMC Cancer, 2018, 18, 724.	2.6	26
13	Selective 14 - 3 - $3\hat{l}^3$ induction quenches p- \hat{l}^2 -catenin Ser 37 /Bax-enhanced cell death in cerebral cortical neurons during ischemia. Cell Death and Disease, 2014, 5, e1184-e1184.	6.3	24
14	RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival. Cell Death and Disease, 2016, 7, e2300-e2300.	6.3	16
15	LIS1 Regulates Osteoclastogenesis through Modulation of M-SCF and RANKL Signaling Pathways and CDC42. International Journal of Biological Sciences, 2016, 12, 1488-1499.	6.4	10
16	Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma. Blood, 2019, 134, 4383-4383.	1.4	3
17	The Co-Occurrence of MAF Translocations in RAS Mutated Multiple Myeloma Confers Resistance to MEK Inhibition. Blood, 2016, 128, 1138-1138.	1.4	2
18	MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma. Blood, 2013, 122, 281-281.	1.4	1

#	Article	IF	CITATIONS
19	Mafb Protein Confers Primary Resistance of Myeloma to Proteasome Inhibitors. Blood, 2014, 124, 2091-2091.	1.4	1
20	Identification of Biomarkers Associated with MAF-Mediated Resistance to Proteasome Inhibitors in $t(14;16)$ Multiple Myeloma. Blood, 2015, 126, 3020-3020.	1.4	1
21	Mutant KRAS and Brafs Upregulate Stress Granules and Mediate Drug Resistance, Which Can be Modulated By Cox2 Inhibition in Multiple Myeloma. Blood, 2018, 132, 3166-3166.	1.4	0
22	N-Cadherin Stabilizes \hat{l}^2 -Catenin and Promotes \hat{l}^2 -Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma. Blood, 2021, 138, 1572-1572.	1.4	0